Keywords: long-term, data, regeneron, axokine, pharmaceuticals, candidate, obesity
Long-term data with Regeneron's Axokine
Article | 13 September 2001
Regeneron Pharmaceuticals' candidate obesity drug Axokine (ciliaryneurotrophic factor) has been shown to maintain weight loss after an initial 12-week treatment ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- Neovacs moving forward in rheumatoid arthritis, say analysts
